<SEC-DOCUMENT>0001213900-16-015528.txt : 20160804
<SEC-HEADER>0001213900-16-015528.hdr.sgml : 20160804
<ACCEPTANCE-DATETIME>20160804080017
ACCESSION NUMBER:		0001213900-16-015528
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160804
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160804
DATE AS OF CHANGE:		20160804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		161805819

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k080416_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the</B><BR>
<B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">Date of Report (Date of earliest event reported): August
4, 2016</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">(Exact name of registrant as
specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0"><B>Delaware</B></TD>
    <TD STYLE="width: 2%; padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0"><B>000-52446</B></TD>
    <TD STYLE="width: 2%; padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0"><B>74-2963609</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0">(State or other jurisdiction<BR>
of incorporation)</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0">(Commission File Number)</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0">(IRS Employer<BR>
Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0"><B>275 Madison Avenue, 7th Floor</B><BR>
<B>New York, NY</B></TD>
    <TD STYLE="width: 2%; padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0"><B>10016</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0">(Address of principal executive offices)</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-align: center; text-indent: 0">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">Registrant&rsquo;s telephone number, including area
code: <B>(732) 243-9495</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1.5pt solid; padding: 0; font-family: Times New Roman,serif; text-align: center"><B>N/A</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-align: center">(Former name or former address, if changed since last report)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: MS Mincho">&#9744;</FONT>
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: MS Mincho">&#9744;</FONT>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: MS Mincho">&#9744;</FONT>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-family: MS Mincho">&#9744;</FONT>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 0 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-family: Times New Roman,serif; text-align: justify"><B>Item 7.01.</B></TD>
    <TD STYLE="width: 90%; font-family: Times New Roman,serif; text-align: justify"><B>Regulation FD Disclosure.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/115% Times New Roman,serif; margin: 0pt 0">Actinium Pharmaceuticals, Inc. issued a press release on August
4, 2016 regarding its mid-year letter to shareholders providing an update on company progress and anticipated milestones<FONT STYLE="color: #4A442A">.
</FONT>A copy of the Company&rsquo;s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
into this Item&nbsp;7.01 by reference. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein
is deemed to be &quot;furnished&quot; and shall not be deemed to be &quot;filed&quot; for purposes of the Securities Exchange
Act of 1934, as amended. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission
as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy
the requirements of Regulation FD.</P>

<P STYLE="font: 10pt/120% Times New Roman,serif; margin: 0pt 0; color: #4A442A">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><B>Item 9.01.</B></TD>
    <TD STYLE="width: 90%"><B>Financial Statements and Exhibits.</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt/120% Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/120% Times New Roman,serif; margin: 0"><I>(d) Exhibits. </I>&nbsp;</P>

<P STYLE="font: 10pt/120% Times New Roman,serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0.7pt; font-family: Times New Roman,serif; width: 10%">Exhibit&nbsp;99.1</TD>
    <TD STYLE="padding: 0.7pt; font-family: Times New Roman,serif; width: 1%">&nbsp;</TD>
    <TD STYLE="padding: 0.7pt; font-family: Times New Roman,serif; width: 89%">Press release of Actinium Pharmaceuticals, Inc., dated August 4, 2016</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding: 0.7pt; font-family: Times New Roman,serif"></TD>
    <TD STYLE="padding: 0.7pt; font-family: Times New Roman,serif">&nbsp;</TD>
    <TD STYLE="padding: 0.7pt; font-family: Times New Roman,serif"></TD></TR>
</TABLE>
<P STYLE="font: 10pt/120% Times New Roman,serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman,serif; margin: 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman,serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0 0 12pt; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0"><B>ACTINIUM PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0; width: 5%">&nbsp;</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0; width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0">Dated: August 4, 2016</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0">By:</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0; border-bottom: Black 1.5pt solid"><I>/s/ Kaushik J. Dave</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0">Name:</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0">Kaushik J. Dave</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0">Title:</TD>
    <TD STYLE="padding: 0; font-family: Times New Roman,serif; text-indent: 0">Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; text-align: center; margin-bottom: 0">3</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k080416ex99i_actinium.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 97.5pt; width: 414pt"></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>Actinium Pharmaceuticals Issues
Mid-Year Letter to Shareholders Providing Update on Company Progress and Anticipated Milestones</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: center"><I>Iomab-B Pivotal Phase 3 Trial Initiation Signals Transformation of Company Profile to Later-Stage
Development </I></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">-</TD><TD STYLE="text-align: center"><I>Actimab-A Progressing into Phase 2 Clinical Trial with Impetus from Phase I Results and Peripheral
Blast Burden Hypothesis Directing To Competitively Higher Response Rates</I></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 4.5pt 10pt 0; text-align: justify"><B>NEW YORK, NY &ndash; August
4, 2016</B> &ndash; Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (&quot;Actinium&quot; or the &ldquo;Company&quot;), a biopharmaceutical
company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the
Company has issued a mid-year letter to shareholders highlighting Actinium&rsquo;s recent progress and anticipated corporate milestones.
The recent progress and anticipated milestones below were featured in the shareholder letter:</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 4.5pt 0pt 0; text-align: justify"><B><U>Key Achievements To-Date
in 2016</U></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Later-stage development focus attained
with initiation of the pivotal Phase 3 SIERRA clinical trial for Iomab-B </B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.25pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Conducted successful Iomab-B Investigator Meeting with over 80 attendees representing 25 of the
top bone marrow transplant centers in the US and Canada</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.25pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Selected Zevacor Pharma, Inc. as our clinical production and supply partner for the SIERRA trial</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.25pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Selected Medpace, Inc. as our Clinical Research Organization (CRO) for the SIERRA trial</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.25pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Further strengthened the clinical development team with new hires in clinical operations, nursing
support and clinical trial management in order to ensure efficient trial execution</TD></TR></TABLE>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>On track to initiate the Phase 2 trial
for Actimab-A with impetus from strong Phase I results that imply potential for a best in class CD33 asset</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.25pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Hosted webinar featuring key scientific luminaries discussing the Peripheral Blast (PB) Burden
Hypothesis, a key discovery from our HuM195-Alpha program</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.25pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Reached agreement with the FDA on certain protocol changes that are expected to facilitate enrollment</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Continued to strengthen competitive
position via regulatory and patent related actions</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.25pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Procured assignment of provisional patent applications from Memorial Sloan Kettering related to
the Alpha Particle Immunotherapy Technology (APIT) platform and drug preparation methods</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.25pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Filed provisional patent application related to commercial scale labeling of Iomab-B</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.25pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Received Orphan Drug Designation from the FDA for Iomab-B</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.25pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="text-align: justify">Initiated pursuit of Orphan Drug Designation in the EU for Iomab-B</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 74.25pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 74.25pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Positive Outlook for the Remainder
of 2016 and Beyond</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Actinium&rsquo;s strategy over the next
two years is to be laser focused on executing both the Iomab-B and Actimab-A clinical trials and achieve clinical milestones in
order to pave the way for regulatory approvals and, where appropriate, facilitate corporate partnerships for these assets. With
the pivotal Phase 3 SIERRA trial for Iomab-B initiated and the Phase 2 portion of the Actimab-A trial imminent, we expect to continue
to evolve into a later-stage development company. To that end, we intend to continue our work to build shareholder value by targeting
the following objectives and milestones for the remainder of 2016 and beyond:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continue to activate leading transplant
BMT centers as SIERRA trial sites</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Work closely with SIERRA clinical trial
sites to drive patient recruitment and enrollment</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initiate the Phase 2 clinical trial for
Actimab-A</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Provide end of year Actimab-A Phase 2
clinical trial update around ASH</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continue to pursue Orphan Drug Designation
for Iomab-B and Actimab-A in the EU</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Identify and pursue strategic initiatives
for the APIT technology platform </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initiate additional clinical trials as
appropriate</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continue to pursue opportunities for licensing,
partnerships and other collaborations as appropriate</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reach patient enrollment in the SIERRA
trial as quickly as possible to initiate first DMC report</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Generate interim data for Actimab-A Phase
2 trial </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Host educational and informational events
targeted at physicians, investors, etc.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Perform analysis of interim data to determine
go-forward development strategy of Actimab-A</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reach next patient enrollment milestone
in the SIERRA trial to initiate second DMC report</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Complete enrollment in Actimab-A Phase
2 study</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reach third patient enrollment milestone
in the SIERRA trial to initiate the third DMC report</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Report topline data from Actimab-A Phase
2 study</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Complete patient enrollment in the SIERRA
trial </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 4.5pt 10pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 4.5pt 10pt 0; text-align: justify"></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 4.5pt 10pt 0; text-align: justify">The shareholder letter can
be accessed via the investor relations section of Actinium&rsquo;s website http://ir.actiniumpharma.com/shareholder-letters.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 4.5pt 10pt 0; text-align: justify">Sandesh Seth, Actinium&rsquo;s
Executive Chairman stated, &ldquo;Actinium set out to make 2016 a transformational year for the Company following the clearance
of our IND for Iomab-B at the end of 2015 and I think it is safe to say that we were successful. Reflecting on the first half of
2016, I could not be more pleased with all that we have accomplished, particularly the initiation of the pivotal Phase 3 clinical
trial for Iomab-B and the many opportunities that lie ahead for Actinium such as the Actimab-A Phase 2 clinical trial. The remainder
of 2016 will be focused on advancing our clinical programs, leveraging our technology platform and driving shareholder value through
continued and consistent execution of milestones.&rdquo;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>About Iomab-B</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Iomab-B is a radioimmunotherapy
consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson
Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially
useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications,
including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic
leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes,
BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most
healthy tissues. Iomab-B is being studied in the pivotal Phase 3 SIERRA trial and is designed to be used, upon approval, in preparing
relapsed or refractory AML patients over the age of 55 patients for hematopoietic stem cell transplant, commonly referred to as
bone marrow transplant.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>About the SIERRA trial</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; color: #282726"><FONT STYLE="background-color: white">The
SIERRA (<B>S</B>tudy of <B>I</B>omab-B in <B>E</B>lderly <B>R</B>elapsed or <B>R</B>efractory <B>A</B>ML) trial is a multi-center,
randomized, controlled pivotal Phase 3 study of Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (AML) who
are over the age of 55. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA)
submission could include the SIERRA trial, if it is successful. The primary endpoint in the pivotal Phase 3 trial is durable complete
remission, defined as a complete remission lasting at least 6 months and the secondary endpoint will be overall survival at one
year. There are currently no effective treatments approved by the FDA for AML in this patient population and there is no defined
standard of care. Iomab-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen
prior to HSCT in various blood cancers, including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of
these studies in almost 300 patients have demonstrated the potential of Iomab-B to create a new treatment paradigm for bone marrow
transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter
and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including
curative potential.</FONT></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B></B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>About Actimab-A</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 4.5pt 10pt 0; text-align: justify">Actimab-A, Actinium's most
advanced alpha particle immunotherapy (APIT) program, is currently in a single arm, multicenter trial Phase 1/2 trial for patients
newly diagnosed with AML over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support
from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy
profile. Actimab-A consists of the monoclonal antibody, HuM195, and the radioisotope, actinium-225. Actinium-225 decays by giving
off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of
which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. HuM195 is the humanized
version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha
particle technology and HuM195 were initially developed at Memorial Sloan Kettering Cancer Center. Actimab-A is a second-generation
therapy from the Company&rsquo;s HuM195-Alpha program, which has now been studied in over 85 patients in four clinical trials.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>About Actinium Pharmaceuticals</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Actinium Pharmaceuticals, Inc.
(www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics
for the treatment of advanced cancers. Actinium's targeted radioimmunotherapy products are based on its proprietary delivery platform
for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting radiopharmaceuticals in
conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used,
upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The
Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or relapsed AML patients over
the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing
its clinical development in a Phase 1/2 trial for patients newly diagnosed with AML over the age of 60 in a single-arm multicenter
trial.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><B>Forward-Looking Statements
for Actinium Pharmaceuticals, Inc. </B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify">This news release contains &quot;forward-looking
statements&quot; as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's
current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth
in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial
performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium
Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information,
future events, or otherwise.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 4.5pt 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Contact:</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Steve O'Loughlin<BR>
Vice President, Finance and Corporate Development<BR>
Actinium Pharmaceuticals, Inc.<BR>
soloughlin@actiniumpharma.com</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; color: #282726">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "< C$# 2(  A$! Q$!_\0
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M#]X,0I'X@FO1PU!*'.]SEJR;=D>SO:F[1HV&0PQBN:C^$UM)>>9\Z1%LE%;
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M=1J5]O)5#Q7(Z[H$/B"W$4R;L'*GN#ZBLC0O%[7^MII5TPD>7=Y4JC'(&=I
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M>7DBH/E3>H XQGIWKH6)I>VIU+Z126W8Y7A*SP]2E;63ON:>F'.CVA]8$_\
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MV2#SI9@O\<K;F/U-6*\U[GK1O97%HHHH*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G-0\(:7?W\]]*'$\Y
M!=@W'"A1^@%5/^$&TO\ O/\ ]]5@:QXCEM?&FIV%U--]E5X_+VR,HCS$A(P#
MT))-6!J-O_S\2?\ @0W^->G"GB7!-2T/G*V+P4:\HRI7=]]#7_X0;2O[S_\
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M?KWHK810IN:5UI9I_FN@8?'.I44)-)ZW333\K,ZFBBBN ]00UY5#_P E,/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2L_4]-COX ,[)4.4<
M=5-:%%--IW1,HJ2L]CRWQ!H.I:IJMEIT$&V8AFEDYV(G WY].O'6NY\.>'+/
MPY8^3;C?,^#-.WWI#_0#L/\ Z];%%;5<3.I%1>QQX7 4L/)RCJW^"'4445@=
MP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
